Suppliers / Bachem Americas

Bachem Americas

United States Updated 9 July 2026

Bachem Americas is an API manufacturer based in United States. It holds 7 active US drug master files and 4 valid CEPs across a filed portfolio of 8 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 June 2024 as VAI.

7
active US DMFs
4
valid CEPs
2
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 June 2024 VAI US FDA
  • 27 March 2023 VAI US FDA
  • 13 December 2019 VAI US FDA
  • 12 June 2019 VAI US FDA
  • 5 February 2019 NAI US FDA
  • 18 May 2018 VAI US FDA
  • 25 February 2016 VAI US FDA
  • 7 November 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Vista, United States 3000718309
Torrance, United States 2024023

What they file, and where

Molecule Regulators Docs
Desmopressin EDQM, US FDA 3
Calcitonin (Salmon) EDQM 2
Exenatide US FDA 1
Lanreotide US FDA 1
Liraglutide US FDA 1
Parathyroid Hormone US FDA 1
Salmon Calcitonin US FDA 1
Vasopressin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Bachem Americas comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 June 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates